Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2021-10-08 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, compliance with regulations, and the timeline of the repurchase program. It does not contain financial statements or earnings data but focuses on the company's buyback activity. The document length is short (1393 characters) and it is clearly an update on the share repurchase progress, fitting the description of a Transaction in Own Shares (POS) filing rather than a full financial report or announcement of a report publication.
2021-10-08 Chinese
关于重大资产重组事项的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of a major asset restructuring involving the acquisition of 100% equity of a target company. It references multiple previous disclosures of draft reports and revisions related to the major asset purchase and related party transactions. The document details the history of disclosures, regulatory inquiries, board meetings, and approvals related to the transaction. It explicitly states that the transaction constitutes a major asset restructuring under relevant regulations and that the transaction requires shareholder approval. The document is a progress update on the major asset restructuring, not the full detailed report itself. It is not a full annual or interim report, audit report, or earnings release. It is not a proxy solicitation or voting results announcement. It is a regulatory announcement about the progress of a major asset restructuring. Therefore, the most appropriate classification is a Regulatory Filing (RNS) as it is a general regulatory announcement about the progress of a major transaction and does not contain the full detailed transaction report itself.
2021-10-08 Chinese
中瑞世联资产评估集团有限公司关于深圳证券交易所《关于对盈康生命科技股份有限公司的重组问询函》的回复
Regulatory Filings Classification · 95% confidence The document is a detailed response from an asset appraisal group to an inquiry from the Shenzhen Stock Exchange regarding a restructuring involving Yingkang Life Technology Co., Ltd. It contains extensive financial forecasts, valuation analysis, and discussion of the fairness and reasonableness of the transaction pricing related to the acquisition of a hospital asset (Suzhou Guangci). The content includes detailed financial data, profit forecasts, valuation multiples, and transaction terms, which are typical components of a restructuring or merger-related disclosure. The document references a "restructuring inquiry letter" and discusses adjustments to the transaction price and performance commitments, indicating it is related to a corporate restructuring or acquisition transaction. This is not a full annual or interim report, nor is it a simple announcement or certification. It is a detailed reply to a regulatory inquiry about a restructuring transaction, which fits best under the category of Regulatory Filings (RNS) as it is a regulatory response document and does not constitute a standalone audit report or full financial report. The document is lengthy (15,000 characters) and contains substantive financial and transaction details but is not a formal financial statement report like a 10-K or IR. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-09-30 Chinese
独立董事关于第五届董事会第十四次（临时）会议相关事项的独立意见
M&A Activity Classification · 95% confidence The document is an independent directors' opinion on a significant asset restructuring and related transactions, including adjustments to the restructuring plan, related agreements, and a review report by an accounting firm. It discusses a major asset acquisition and related governance and compliance matters. The content focuses on a major asset reorganization and related corporate actions, which aligns with announcements and documents related to merger proposals or takeover bids. The document is not a full annual or interim report, nor is it a simple announcement or certification. It fits best under the category of M&A Activity (TAR). The document length is 1550 characters, which is short but contains substantive content about the transaction and related approvals, not just an announcement or notice.
2021-09-30 Chinese
重大资产购买暨关联交易报告书（草案）（四次修订稿）摘要
Capital/Financing Update Classification · 95% confidence The document is titled as a "重大资产购买暨关联交易报告书（草案）（四次修订稿）摘要" which translates to "Major Asset Purchase and Related Party Transaction Report (Draft) (Fourth Revision) Summary." It details a significant asset purchase transaction by 盈康生命科技股份有限公司, including transaction parties, asset valuation, financial impacts, and approvals. The document includes detailed financial data, transaction terms, and legal and audit references. It is a comprehensive report on a major asset acquisition and related party transaction, not merely an announcement or summary. This fits the category of a Capital/Financing Update (CAP) as it relates to a major asset purchase and financing transaction update. It is not an Annual Report, Audit Report, or other categories. The document length (15,000 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-09-30 Chinese
第五届监事会第十四次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 14th extraordinary meeting of the 5th Supervisory Board of Yingkang Life Technology Co., Ltd. It discusses adjustments to a major asset restructuring and related agreements, including the purchase of 100% equity in a subsidiary, payment terms, performance commitments, and related legal and financial arrangements. The document includes voting results and mentions that these resolutions will be submitted to the shareholders' meeting for approval. It is not a full financial report, audit report, or earnings release, but rather a formal announcement of board-level decisions related to a major asset acquisition and restructuring. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management regarding significant corporate actions.
2021-09-30 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.